/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Cellectis S.A.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$4.66 -0.0106(-1.06%) CLLS at 04 Dec 2025 04:28 PM Biotechnology
Lowest Today 4.52
Highest Today 4.71
Today’s Open 4.64
Prev. Close 4.71
52 Week High 5.48
52 Week Low 1.10
Day’s Range: Low 4.52 High 4.71
52-Week Range: Low 1.10 High 5.48
1 day return -
1 Week return -7.9
1 month return +41.21
3 month return +79.23
6 month return +225.87
1 year return +147.21
3 year return +108.96
5 year return -84.17
10 year return -

Institutional Holdings

Long Focus Capital Management, LLC 4.70

B Group, Inc 3.25

UBS Asset Mgmt Americas Inc 3.17

UBS Lux Dgtl Hlth Eq Fd seeding P acc 1.30

Macquarie Group Ltd 0.23

Macquarie Healthcare I 0.23

Galileo - Biotech Innovation Fund S USD 0.23

Morgan Stanley - Brokerage Accounts 0.09

LPL Financial Corp 0.09

BNP Paribas Arbitrage, SA 0.04

Millennium Management LLC 0.04

Susquehanna International Group, LLP 0.03

Prisma Cube 0.03

P & S Renditefonds T 0.03

First Affirmative Financial Network 0.03

UBS Group AG 0.03

Wells Fargo & Co 0.02

HARBOUR INVESTMENTS, INC. 0.00

Rhumbline Advisers 0.00

JPMorgan Chase & Co 0.00

Hanson Mcclain Inc 0.00

POM Investment Strategies, LLC 0.00

Principal Securities Inc 0.00

Advisor Group Holdings, Inc. 0.00

Bank of America Corp 0.00

Market Status

Strong Buy: 1

Buy: 2

Hold: 2

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 488.94 M

PB Ratio 4.6131

PE Ratio 0.0

Enterprise Value 418.71 M

Total Assets 383.54 M

Volume 52670

Company Financials

Annual Revenue FY23:16496000 16.5M, FY22:19171000 19.2M, FY21:73949000 73.9M, FY20:73949000 73.9M, FY19:15190000 15.2M

Annual Profit FY23:15235000 15.2M, FY22:17399000 17.4M, FY21:37674000 37.7M, FY20:37674000 37.7M, FY19:3798000 3.8M

Annual Net worth FY23:-85010000 -85.0M, FY22:-98688000 -98.7M, FY21:-86280000 -86.3M, FY20:-72571000 -72.6M, FY19:-90686000 -90.7M

Quarterly Revenue Q3/2025:35172000 35.2M, Q2/2025:16725000 16.7M, Q1/2025:10655000 10.7M, Q3/2024:16200000 16.2M, Q2/2024:8061000 8.1M

Quarterly Profit Q3/2025:32815000 32.8M, Q2/2025:14300000 14.3M, Q1/2025:8640000 8.6M, Q3/2024:11480000 11.5M, Q2/2024:3333000 3.3M

Quarterly Net worth Q3/2025:589000 0.6M, Q2/2025:-23735000 -23.7M, Q1/2025:-18128000 -18.1M, Q3/2024:-23056000 -23.1M, Q2/2024:-25270000 -25.3M

Fund house & investment objective

Company Information Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.

Organisation Biotechnology

Employees 216

Industry Biotechnology

CEO Dr. Andre Choulika Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow